Synopsis
Recognise when an environmental non-tuberculous mycobacterium represents progressive pulmonary disease rather than transient isolation, and frame diagnosis, observation and species-led multidrug treatment safely with an experienced NTM service. Confirm treatment decisions against current BTS guidance, microbiology advice and local policy.
- A positive culture is not synonymous with disease: combine compatible symptoms, characteristic imaging and reproducible microbiology, while excluding tuberculosis and convincing alternatives.
- Bronchiectasis, COPD, previous tuberculosis, cystic fibrosis, thoracic skeletal abnormality, low body mass and immune compromise increase susceptibility, but NTM can also occur without an obvious host defect.
- Send at least two sputum samples collected on separate days for mycobacterial culture; ask for species or subspecies identification and appropriate susceptibility testing.
- High-resolution CT distinguishes nodular-bronchiectatic disease from fibrocavitary or disseminated patterns and provides a baseline for multidisciplinary decisions.
- Stable, mildly symptomatic disease may be observed with structured surveillance; cavitation, smear positivity, systemic illness or radiological progression shifts the balance towards treatment.
- Never use macrolide monotherapy for MAC pulmonary disease: acquired macrolide resistance can remove the most important active oral drug.
- Treatment is prolonged, toxic and species-specific, usually continuing for at least 12 months after culture conversion; specialist oversight and shared decisions are essential.
- Until Mycobacterium tuberculosis has been reasonably excluded, use the local infection-control pathway for potentially infectious pulmonary TB rather than assuming NTM.
Key red flags
Upper-lobe cavities, pleural thickening, weight loss, night sweats and haemoptysis can closely mimic pulmonary tuberculosis or malignancy. COPD, smoking-related lung damage and previous TB are common backgrounds.
Hypoxaemia, major haemoptysis, sepsis physiology, rapid radiological spread or extrapulmonary features in profound immune compromise require acute stabilisation, urgent respiratory-infection input and assessment for disseminated infection.
Investigation priorities
Obtain at least two expectorated samples on separate days, ideally before NTM-active antibiotics, and request acid-fast microscopy, culture and species-level identification.
Management branches
An NTM is reported from a respiratory specimen.
- Review symptoms, specimen quality, species identity, smear burden, exposures, immune state and previous imaging; urgently retain TB precautions if M. tuberculosis complex remains plausible.
- Arrange high-resolution CT and further sputum cultures on separate days; use bronchoscopy only when it will materially resolve uncertainty and the patient can tolerate it.
- Discuss concordant clinical, radiological and microbiological evidence in an NTM-experienced multidisciplinary setting, document whether criteria are met and name important alternatives.
- Explain uncertainty to the patient and ensure ownership of pending reference-laboratory results.
Diagnostic criteria are met or nearly met, but disease is mild and stable and treatment harm may exceed near-term benefit.
- Agree goals and optimise airway clearance, nutrition, smoking cessation, reflux or aspiration management and bronchiectasis care.
- Record baseline symptoms, weight, sputum status, lung function and CT, then schedule clinical and sputum reviews at a frequency matched to risk.
- Escalate for new cavitation, smear positivity, repeated cultures with increasing burden, haemoptysis, weight loss, functional decline or objective radiological progression.